Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials
Study Connect™, a new mobile app from Merge eClinical, allow users of its eClinicalOS (eCOS) to perform a wide array of clinical trial management functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect™enables researchers to:
· Manage randomization of subjects
· Coordinate dispensing and inventory management
· Unblind individual subjects, as circumstances warrant
· Stay connected with real-time customized notifications
· Monitor enrollment and establish milestone alerts
· Share top-level statistics for each study with key stakeholders using the study dashboard
· Expedite approval response times for critical study decisions such as patient study eligibility
· Maintain security with the ability to set customized role-based permissions for individual studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.